UMike
Klutzing in Thai
- Joined
- 16 January 2007
- Posts
- 1,481
- Reactions
- 1,847
expecting the interim report for the phase 3 trial into lower back pain
Up just over 10% today and closed at $1.40Chart looks to be in a pivotal position … if it can get above the recent triple top around $1.27 it could start to wriggle up a bit.
Up just over 10% today and closed at $1.40
Battle continues, higher lows, looks like keen buying to me.
Forming a wedge. Yesterday seemed quite bullish to me, price dropped and then just before the end of the day someone bought everything they could to take it to a rise.
(Sorry no graph, can't work how to do it from Bell Direct)
I have noticed there is a lot of accumulation going on. There is a lot of interest in this company which has some outstanding phase 3 trials due early next year and this company SP will take off.
It could be this month.
Mesoblast will receive up to US$150 million in upfront and milestone payments prior to product launch, as well as further commercialisation milestone payments. These payments include commitments up to US$45 million within the first year comprising US$15 million on signing, US$20 million on receiving regulatory approval to begin a confirmatory Phase III trial in Europe, and US$10 million on certain clinical and manufacturing outcomes. Cumulative milestone payments could exceed US$1 billion depending on the final outcome of Phase III studies and patient adoption. Mesoblast will also receive tiered double digit royalties on product sales.
MSB is a serial pump-dump biotech. And this announcement takes the cake. As a general rule, degenerative discs don't cause pain. So they're coming up with a solution to a non-problem. Pain is a problem (a huge market, as you point out), but very rarely does it have anything to do with DDD.You weren't far off Knobby. It's certainly moving today after announcing that it has entered into a strategic partnership with Grünenthal, a global leader in pain management, to develop and commercialise MPC-06-ID, a Phase III allogeneic cell therapy candidate for the treatment of chronic low back pain due to degenerative disc disease in patients who have exhausted conservative treatment options.
Under the partnership, Grünenthal will have exclusive commercialisation rights to MPC-06-ID for Europe and Latin America.
The announcement continues:
Sounds like it could be a pretty lucrative deal if all goes well. Lower back pain is an affliction that many people deal with, especially in middle and old age. I imagine the global market for this treatment would be huge.
MSB currently up 16.8% to $1.70 following the announcement on solid volume of more than 3 million shares. Looking good.
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?